Complement and fungal pathogens: An update

Mycoses

Volumn 51, Issue 6, 2008, Pages 477-496

  Speth, Cornelia ^a   Rambach, Günter ^a   Würzner, Reinhard ^a   Lass Flörl, Cornelia ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Adhesion; Antifungal activity; Aspergillus

Indexed keywords

FUNGAL PROTEIN;

ADAPTIVE IMMUNITY; ALLERGY; ANTIMICROBIAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; BLASTOMYCOSIS; CANDIDA; CANDIDIASIS; CELL ADHESION; COMPLEMENT SYSTEM; CRYPTOCOCCUS; FUNGUS; HISTOPLASMA; HUMAN; IMMUNE RESPONSE; MYCOSIS; NONHUMAN; PARACOCCIDIOIDES; PATHOGENESIS; PNEUMOCYSTIS; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW;

ANIMALS; COMPLEMENT SYSTEM PROTEINS; FUNGI; HUMANS; MYCOSES;

ASPERGILLUS; FUNGI; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 53549117741     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2008.01597.x     Document Type: Review

References (163)

1. Martino R, Subira M. Invasive fungal infections in hematology: new trends. Ann Hematol 2002 81 : 233 43.
2. Speth C, Lass-Flörl C, Würzner R. Complement in fungal infections and complement evasion strategies. In : Brown GD, Netea MG (eds Immunology of Fungal Infections. Dordrecht, The Netherlands : Springer, 2007 : 177 200.
3. Speth C, Würzner R, Stoiber H, Dierich MP. The complement system: pathophysiology and clinical relevance. Wien Klin Wochenschr 1999 111/10 : 378 91.
4. Prodinger WM, Würzner R, Stoiber H, Dierich MP. Complement. In : Paul WE (ed. Fundamental Immunology. Philadelphia : Lippincott-Raven Publishers, 2003 : 1077 103.
5. Chen Z, Koralov SB, Kelsoe G. Regulation of the humoral immune responses by DC21/CD35. Immunol Rev 2000 176 : 194 204.
6. Köhl J. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol 2001 38 : 175 87.
7. Gerard NP, Lu B, Liu P et al. An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J Biol Chem 2005 280 : 39677 80.
8. Markiewski MM, Lambris D. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 2007 171 : 715 27.
9. Krych-Goldberg M, Atkinson JP. Structure-function relationships of complement receptor type 1. Immunol Rev 2001 180 : 112 22.
10. Ellis M. Invasive fungal infections: evolving challenges for diagnosis and therapeutics. Mol Immunol 2002 38 : 947 57.
11. Würzner R. Complement and infectious diseases. Contrib Microbiol 2003 10 : 1 17.
12. Speth C, Dierich MP, Gasque P. Neuroinvasion by pathogens: a key role of the complement system. Mol Immunol 2002 38 : 669 79.
13. Mavor AL, Thewes S, Hube B. Systemic fungal infections caused by Candida species: epidemiology, infection process and virulence attributes. Curr Drug Targets 2005 6 : 863 74.
14. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006 20 : 485 506.
15. Sobel JD. Vulvovaginal candidosis. Lancet 2007 369 : 1961 71.
16. Liu F, Liao Q, Liu Z. Mannose-binding lectin and vulvovaginal candidiasis. Int J Gynaecol Obstet 2006 92 : 43 47.
17. Lukasser-Vogl E, Gruber A, Lass-Flörl C et al. Membrane attack complex formation on yeast as trigger of selective release of terminal complement proteins from human polymorphonuclear leukocytes. FEMS Immunol Med Microbiol 2000 28 : 15 23.
18. Babula O, Lazdane G, Kroica J, Ledger WJ, Witkin SS. Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in latvian women. Clin Infect Dis 2003 37 : 733 7.
19. Giraldo PC, Babula O, Goncalves AK et al. Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. Obstet Gynecol 2007 109 : 1123 8.
20. Gelfand JA, Hurley DL, Fauci AS, Frank MM. Role of complement in host defense against experimental disseminated candidiasis. J Infect Dis 1978 138 : 9 16.
21. Kozel TR, Weinhold LC, Lupan DM. Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans. Infect Immun 1996 64 : 3360 8.
22. Rambach G, Speth C. Complement in Candida albicans infections. Front Biosci 2008 in press.
23. Zhang MX, Kozel TR. Mannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albicans via the alternative complement pathway. Infect Immun 1998 66 : 4845 50.
24. Zhang MX, Cutler JE, Han Y, Kozel TR. Contrasting roles of mannan-specific monoclonal immunoglobulin M antibodies in the activation of classical and alternative pathways by Candida albicans. Infect Immun 1998 66 : 6027 9.
25. Han Y, Kozel TR, Zhang MX, McGill RS, Carroll MC, Cutler JE. Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. J Immunol 2001 167 : 1550 7.
26. Cutler JE. Defining criteria for anti-mannan antibodies to protect against candidiasis. Curr Mol Med 2005 5 : 383 92.
27. Xin H, Cutler JE. Hybridoma passage in vitro may result in reduced ability of antimannan antibody to protect against disseminated candidiasis. Infect Immun 2006 74 : 4310 21.
28. Lillegard JB, Sim RB, Thorkildson P, Gates MA, Kozel TR. Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo. J Infect Dis 2006 193 : 1589 97.
29. Ip WK, Lau YL. Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells. J Infect Dis 2004 190 : 632 40.
30. Brouwer N, Dolman KM, van Houdt M, Sta M, Roos D, Kuijpers TW. Mannose-binding lectin (MBL) facilitates opsonophagocytosis of yeasts but not of bacteria despite MBL binding. J Immunol 2008 180 : 4124 32.
31. Kozel TR. Activation of the complement system by pathogenic fungi. Clin Microbiol Rev 1996 9 : 34 46.
32. Kozel TR, McGill RS, Percival A, Zhou Q. Biological activities of naturally occurring antibodies reactive with Candida albicans mannan. Infect Immun 2004 72 : 209 18.
33. Gruber A, Lukasser-Vogl E, Borg-von Zepelin M, Dierich MP, Würzner R. Human immunodeficiency virus type 1 gp160 and gp41 binding to Candida albicans selectively enhances candidal virulence in vitro. J Infect Dis 1998 177 : 1057 63.
34. Zhang MX, Bohlmann MC, Itatani C et al. Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice. Infect Immun 2006 74 : 362 9.
35. Forsyth CB, Mathews HL. Lymphocytes utilize CD11b/CD18 for adhesion to Candida albicans. Cell Immunol 1996 170 : 91 100.
36. Forsyth CB, Plow EF, Zhang L. Interaction of the fungal pathogen Candida albicans with integrin CD11b/CD18: recognition by the I domain is modulated by the lectin-like domain and the CD18 subunit. J Immunol 1998 161 : 6198 205.
37. Lavigne M, Albina JE, Reichner JS. Beta-glucan is a fungal determinant for adhesion-dependent human neutrophil functions. J Immunol 2006 177 : 8667 75.
38. Rubin-Bejerano I, Abeijon C, Magnelli P, Grisafi P, Fink GR. Phagocytosis by human neutrophils is stimulated by a unique fungal cell wall component. Cell Host Microbe 2007 2 : 55 67.
39. Forsyth CB, Mathews HL. Lymphocyte adhesion to Candida albicans. Infect Immun 2002 70 : 517 27.
40. Romani L, Montagnoli C, Bozza S et al. The exploitation of distinct recognition receptors in dendritic cells determines the full range of host immune relationships with Candida albicans. Int Immunol 2004 16 : 149 61.
41. Ghezzi MC, Raponi G, Angeletti S, Mancini C. Serum-mediated enhancement of TNF-alpha release by human monocytes stimulated with the yeast form of Candida albicans. J Infect Dis 1998 178 : 1743 9.
42. Sonesson A, Ringstad L, Nordahl EA, Malmsten M, Mörgelin M, Schmidtchen A. Antifungal activity of C3a and C3a-derived peptides against Candida. Biochim Biophys Acta 2007 1768 : 346 58.
43. Mullick A, Elias M, Picard S et al. Dysregulated inflammatory response to Candida albicans in a C5-deficient mouse strain. Infect Immun 2004 72 : 5868 76.
44. Mullick A, Leon Z, Min-Oo G et al. Cardiac failure in C5-deficient A/J mice after Candida albicans infection. Infect Immun 2006 74 : 4439 51.
45. Würzner R. Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry. Mol Immunol 1999 36 : 249 60.
46. Kaminishi H, Miyaguchi H, Tamaki T et al. Degradation of humoral host defense by Candida albicans proteinase. Infect Immun 1995 63 : 984 8.
47. Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 2003 67 : 400 28.
48. Lian CH, Liu WD. Differential expression of Candida albicans secreted aspartyl proteinase in human vulvovaginal candidiasis. Mycoses 2007 50 : 383 90.
49. Meri T, Hartmann A, Lenk D et al. The yeast Candida albicans binds complement regulators factor H and FHL-1. Infect Immun 2002 70 : 5185 92.
50. Meri T, Blom AM, Hartmann A, Lenk D, Meri S, Zipfel PF. The hyphal and yeast forms of Candida albicans bind the complement regulator C4b-binding protein. Infect Immun 2004 72 : 6633 41.
51. Blom AM. Strategies developed by bacteria and virus for protection from the human complement system. Scand J Clin Lab Invest 2004 64 : 479 96.
52. Zipfel PF, Würzner R, Skerka C. Complement evasion of pathogens: common strategies are shared by diverse organisms. Mol Immunol 2007 44 : 3850 7.
53. Poltermann S, Kunert A, von der Heide M, Eck R, Hartmann A. Gpm1p is a factor H-, FHL-1, and plasminogen-binding surface protein of Candida albicans. J Biol Chem 2007 282 : 37537 44.
54. Blom AM, Villoutreix BO, Dahlbäck B. Complement inhibitor C4b-binding protein-friend or foe in the innate immune system? Mol Immunol 2004 40 : 1333 46.
55. Brodeur SR, Angelini F, Bacharier LB et al. C4b-binding protein (C4BP) activates B cells through the CD40 receptor. Immunity 2003 18 : 837 48.
56. Gilmore BJ, Retsinas EM, Lorenz JS, Hostetter MK. An iC3b receptor on Candida albicans: structure, function, and correlates for pathogenicity. J Infect Dis 1988 157 : 38 46.
57. Gustafson KS, Vercellotti GM, Bendel CM, Hostetter MK. Molecular mimicry in Candida albicans. Role of an integrin analogue in adhesion of the yeast to human endothelium. J Clin Invest 1991 87 : 1896 902.
58. Bendel CM, Hostetter MK. Distinct mechanisms of epithelial adhesion for Candida albicans and Candida tropicalis. Identification of the participating ligands and development of inhibitory peptides. J Clin Invest 1993 92 : 1840 9.
59. Ollert MW, Wadsworth E, Calderone RA. Reduced expression of the functionally active complement receptor for iC3b but not for C3d on an avirulent mutant of Candida albicans. Infect Immun 1990 58 : 909 13.
60. Gale C, Finkel D, Tao N et al. Cloning and expression of a gene encoding an integrin-like protein in Candida albicans. Proc Natl Acad Sci USA 1996 93 : 357 61.
61. Moors MA, Stull TL, Blank KJ, Buckley HR, Mosser DM. A role for complement receptor-like molecules in iron acquisition by Candida albicans. J Exp Med 1992 175 : 1643 51.
62. Valdimarsson H, Vikingsdottir T, Bang P et al. Human plasma-derived mannose-binding lectin: a phase I safety and pharmacokinetic study. Scand J Immunol 2004 59 : 97 102.
63. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998 26 : 781 803.
64. Schwartz S, Thiel E. Update on the treatment of cerebral aspergillosis. Ann Hematol 2004 83 (Suppl. 1 S42 4.
65. Gibson PG. Allergic bronchopulmonary aspergillosis. Semin Respir Crit Care Med 2006 27 : 185 91.
66. Kozel TR, Wilson MA, Farrell TP, Levitz SM. Activation of C3 and binding to Aspergillus fumigatus conidia and hyphae. Infect Immun 1989 57 : 3412 7.
67. Sturtevant JE, Latgé JP. Interactions between conidia of Aspergillus fumigatus and human complement component C3. Infect Immun 1992 60 : 1913 8.
68. Rosas AL, MacGill RS, Nosanchuk JD, Kozel TR, Casadevall A. Activation of the alternative pathway by fungal melanins. Clin Diagn Lab Immunol 2002 9 : 144 9.
69. Neth O, Jack DL, Dodds AW, Holzel H, Klein NJ, Turner MW. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 2000 68 : 688 93.
70. Hector RF, Yee E, Collins MS. Use of DBA/2N mice in models of systemic candidiasis and pulmonary and systemic aspergillosis. Infect Immun 1990 58 : 1476 8.
71. Henwick S, Hetherington SV, Patrick CC. Complement binding to Aspergillus conidia correlates with pathogenicity. J Lab Clin Med 1993 122 : 27 35.
72. Sturtevant J, Latgé JP. Participation of complement in the phagocytosis of the conidia of Aspergillus fumigatus by human polymorphonuclear cells. J Infect Dis 1992 166 : 580 6.
73. Rambach G, Hagleitner M, Mohsenipour I et al. Antifungal activity of the local complement system in cerebral aspergillosis. Microbes Infect 2005 7 : 1285 95.
74. Laxalt KA, Kozel TR. Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformans. Infect Immun 1979 26 : 435 40.
75. Waldorf AR, Diamond RD. Neutrophil chemotactic responses induced by fresh and swollen Rhizopus oryzae spores and Aspergillus fumigatus conidia. Infect Immun 1985 48 : 458 63.
76. Ames RS, Li Y, Sarau HM et al. Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J Biol Chem 1996 271 : 20231 4.
77. Gerard NP, Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature 1991 349 : 614 7.
78. desArg enhance the susceptibility of monocyte-derived macrophages to HIV infection. J Immunol 2000 166 : 3410 5.
79. Daniels RH, Houston WA, Petersen MM, Williams JD, Williams BD, Morgan BP. Stimulation of human rheumatoid synovial cells by non-lethal complement membrane attack. Immunology 1990 69 : 237 42.
80. Schonermark M, Deppisch R, Riedasch G, Rother K, Mansch GM. Induction of mediator release from human glomerular mesangial cells by the terminal complement components C5b-9. Int Arch Allergy Appl Immunol 1991 96 : 331 7.
81. Tsai HF, Chang YC, Washburn RG, Wheeler MH, Kwon-Chung KJ. The developmentally regulated alb1 gene of Aspergillus fumigatus: its role in modulation of conidial morphology and virulence. J Bacteriol 1998 180 : 3031 8.
82. Tsai HF, Washburn RG, Chang YC, Kwon-Chung KJ. Aspergillus fumigatus arp1 modulates conidial pigmentation and complement deposition. Mol Microbiol 1997 26 : 175 84.
83. Vogl G, Lesiak I, Jensen DB et al. Immune evasion by acquisition of complement inhibitors: the mould Aspergillus binds both factor H and C4b binding protein. Mol Immunol 2008 45 : 1485 93.
84. Behnsen J, Hartmann A, Schmaler J, Gehrke A, Brakhage AA, Zipfel PF. The opportunistic human pathogenic fungus Aspergillus fumigatus evades the host complement system. Infect Immun 2008 76 : 820 7.
85. Washburn RG, Hammer CH, Bennett JE. Inhibition of complement by culture supernatants of Aspergillus fumigatus. J Infect Dis 1986 154 : 944 51.
86. Washburn RG, DeHart DJ, Agwu DE, Bryant-Varela BJ, Julian NC. Aspergillus fumigatus complement inhibitor: production, characterization and purification by hydrophobic interaction and thin-layer chromatography. Infect Immun 1990 58 : 3508 15.
87. Tomee JFC, Kauffman HF. Putative virulence factors of Aspergillus fumigatus. Clin Exp Allergy 2000 30 : 476 84.
88. Kaur S, Gupta VK, Shah A, Thiel S, Sarma PU, Madan T. Elevated levels of mannan-binding lectin (MBL) and eosinophilia in patients of bronchial asthma with allergic rhinitis and allergic bronchopulmonary aspergillosis associate with a novel intronic polymorphism in MBL. Clin Exp Immunol 2006 143 : 414 9.
89. Hogaboam CM, Takahashi K, Ezekowitz RAB, Kunkel SL, Schuh JM. Mannose-binding lectin deficiency alters the development of fungal asthma: effects on airway response, inflammation, and cytokine profile. J Leukoc Biol 2004 75 : 805 14.
90. Humbles AA, Lu B, Nilsson CA et al. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 2000 406 : 998 1001.
91. Krug N, Tschernig T, Erpenbeck VJ, Hohlfeld JM, Köhl J. Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am J Respir Crit Care Med 2001 164 : 1841 3.
92. Nakano Y, Morita S, Kawamoto A, Suda T, Chida K, Nakamura H. Elevated complement C3a in plasma from patients with severe acute asthma. J Allergy Clin Immunol 2003 112 : 525 30.
93. Wills-Karp M. Complement activation pathways: a bridge between innate and adaptive immune responses in asthma. Proc Am Thorac Soc 2007 4 : 247 51.
94. Drouin SM, Corry DB, Hollman TJ, Kildsgaard J, Wetsel RA. Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2002 169 : 5926 33.
95. Abe M, Shibata K, Akatsu H et al. Contribution of anaphylatoxin C5a to late airway responses after repeated exposure of antigen to allergic rats. J Immunol 2001 167 : 4651 60.
96. Peng T, Hao L, Madri JA et al. Role of C5 in the development of airway inflammation, airway hyperresponsiveness, and ongoing airway response. J Clin Invest 2005 115 : 1590 600.
97. Crosdale DJ, Poulton KV, Ollier WE, Thomson W, Denning DW. Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis. J Infect Dis 2001 184 : 653 6.
98. Kaur S, Gupta VK, Thiel S, Sarma PU, Madan T. Protective role of mannan-binding lectin in a murine model of invasive pulmonary aspergillosis. Clin Exp Immunol 2007 148 : 382 9.
99. Walsh MC, Bourcier T, Takahashi K et al. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol 2005 175 : 541 6.
100. Baelder R, Fuchs B, Bautsch W et al. Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation. J Immunol 2005 174 : 783 9.
101. Good CB, Coax WA. Cryptococcal infection in patients with AIDS. N Engl J Med 1990 322 : 243 7.
102. Tucker SC, Casadevall A. Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc Natl Acad Sci USA 2002 99 : 3165 70.
103. Diamond RD, May JE, Kane MA, Frank MM, Bennett JE. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol 1974 112 : 2260 70.
104. Rhodes JC. Contribution of complement component C5 to the pathogenesis of experimental murine cryptococcosis. Sabouraudia 1985 23 : 225 34.
105. Shapiro S, Beenhouwer DO, Feldmesser M et al. Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3. Infect Immun 2002 70 : 2598 604.
106. Kozel TR. Opsonization and phagocytosis of Cryptococcus neoformans. Arch Med Res 1993 24 : 211 8.
107. Kelly RM, Chen J, Yauch LE, Levitz SM. Opsonic requirements for dendritic-mediated responses to Cryptococcus neoformans. Infect Immun 2005 73 : 592 8.
108. Young BJ, Kozel TR. Effects of strain variation, serotype and structural modification on the kinetics for activation and binding of C3 to Cryptococcus neoformans. Infect Immun 1993 61 : 2966 72.
109. Kozel TR, Tabuni A, Young BJ, Levitz SM. Influence of opsonization conditions on C3 deposition and phagocyte binding of large- and small-capsule Cryptococcus neoformans cells. Infect Immun 1996 64 : 2336 8.
110. Kozel TR. Complement activation by pathogenic fungi. Res Immunol 1998 149 : 309 20.
111. Gates MA, Kozel TR. Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans. Infect Immun 2006 74 : 3096 106.
112. Zaragoza O, Taborda CP, Casadevall A. The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur J Immunol 2003 33 : 1957 67.
113. Zaragoza O, Casadevall A. Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance. Cell Microbiol 2006 8 : 1862 76.
114. Marques MB, Kasper DL, Pangburn MK, Wessels MR. Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun 1992 60 : 3986 93.
115. Wilkinson BJ, Sisson SP, Kim Y, Peterson PK. Localization of the third component of complement on the cell wall of encapsulated Staphylococcus aureus M: implications for the mechanism of resistance to phagocytosis. Infect Immun 1979 26 : 1159 63.
116. Blackstock R, Murphy JW. Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans. Infect Immun 1997 65 : 4114 21.
117. Levitz SM, Tabuni A. Binding of Cryptococcus neoformans by human cultured macrophages: requirements for multiple complement receptors and actin. J Clin Invest 1991 687 : 528 35.
118. Levitz SM, Tabuni A, Kozel TR, MacGill RS, Ingalls RR, Golenbock DT. Binding of Cryptococcus neoformans to heterologously expressed human complement receptors. Infect Immun 1997 65 : 931 5.
119. Taborda CP, Casadevall A. CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity 2002 16 : 791 802.
120. Luo Y, Tucker SC, Casadevall A. Fc- and complement-receptor activation stimulates cell cycle progression of macrophage cells from G1 to S. J Immunol 2005 174 : 7226 33.
121. Vecchiarelli A, Retini C, Casadevall A, Monari C, Pietrella D, Kozel TR. Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans. Infect Immun 1998 66 : 4324 30.
122. Matsushima K, Oppenheim JJ. Interleukin-8 and MCAF: novel inflammatory cytokines inducible by IL-1 and TNF. Cytokine 1989 1 : 2 13.
123. Liles WC, Van Hoorhis WC. Nomenclature and biological significance of cytokines involved in inflammation and the last immune response. J Infect Dis 1995 172 : 1573 80.
124. Monari C, Casadevall A, Pietrella D, Bistoni F, Vecchiarelli A. Neutrophils from patients with advanced human immunodeficiency virus infection have impaired complement receptor function and reserved Fcγ receptor function. J Infect Dis 1999 180 : 1542 9.
125. Delfino D, Cianci L, Migliardo M et al. Tumor necrosis factor-inducing activities of Cryptococcus neoformans components. Infect Immun 1996 64 : 5199 204.
126. Levitz SM, Tabuni A, Kornfeld H, Reardon CC, Golenbock DT. Production of tumor necrosis factor alpha in human leukocytes stimulated by Cryptococcus neoformans. Infect Immun 1994 62 : 1975 81.
127. Cross CE, Collins HL, Bancroft GJ. CR3-dependent phagocytosis by murine macrophages: different cytokines regulate ingestion of a defined CR3 ligand and complement-opsonised Cryptococcus neoformans. Immunology 1997 91 : 289 96.
128. Dong ZM, Murphy JW. Cryptococcal polysaccharides bind to CD18 on human neutrophils. Infect Immun 1997 65 : 557 63.
129. Monari C, Kozel TR, Bistoni F, Vecchiarelli A. Modulation of C5aR expression on human neutrophils by encapsulated and acapsular Cryptococcus neoformans. Infect Immun 2002 70 : 3363 70.
130. Luberto C, Martinez-Mariño B, Taraskiewicz D et al. Identification of App1 as a regulator of phagocytosis and virulence of Cryptococcus neoformans. J Clin Invest 2003 112 : 1080 94.
131. Mackinnon JM. On the importance of South American Blastomycosis. Mycopathologia 1970 41 : 187 93.
132. Borges-Walmsley MI, Chen D, Shu X, Walmsley AR. The pathobiology of Paracoccidioides brasiliensis. Trends Microbiol 2002 10 : 80 7.
133. Calich VL, Kipnis TL, Mariano M, Neto CF, Dias da Silva WD. The activation of the complement system by Paracoccidioides brasiliensis in vitro: its opsonic effect and possible significance for an in vivo model of infection. Clin Immunol Immunopathol 1979 12 : 21 30.
134. Munk ME, Kajdacsy-Balla A, Del Negro G, Cuce LC, Da Silva WD. Activation of human complement system in paracoccidioidomycosis. J Med Vet Mycol 1992 30 : 317 21.
135. De Messias IT, Mohren D. Classical and alternative complement pathway activation in paracoccidioidomycosis. J Investig Allergol Clin Immunol 1994 4 : 91 5.
136. Crott LS, Valim YM, Silva CL, Barbosa JE. The role of the complement system in the neutrophil functions stimulated in vitro by an alkali-insoluble cell wall fraction of Paracoccidioides brasiliensis. J Med Vet Mycol 1993 31 : 17 27.
137. Crott LSP, Lucisano-Valim YM, Silva CL, Barbosa JE. Interactions of F1 fractions from different strains of Paracoccidioides brasiliensis with human complement and with human neutrophils. Mycopathologia 1997 140 : 19 27.
138. De Messias IJ, Reis A, Brenden M, Queiroz-Telles F, Mauff G. Association of major histocompatibility complex class III complement components C2, BF and C4 with Brazilian paracoccidioidomycosis. Complement Inflamm 1991 8 : 288 93.
139. Jiménez Mdel P, Restrepo A, Radzioch D, Cano LE, García LF. Importance of complement 3 and mannose receptors in phagocytosis of Paracoccidioides brasiliensis conidia by Nramp1 congenic macrophages lines. FEMS Immunol Med Microbiol 2006 47 : 56 66.
140. Da Silva MB, Marques AF, Nosanchuk JD, Casadevall A, Travassos LR, Taborda CP. Melanin in the dimorphic fungal pathogen Paracoccidioides brasiliensis: effects on phagocytosis, intracellular resistance and drug susceptibility. Microbes Infect 2006 8 : 197 205.
141. De Agostino Biella C, Uecker M, Fernandes da Silva M, Barbosa JE, Silva CL, Crott LS. Investigation of the role of complement and complement receptors in the modulation of B cell activation by a Paracoccidioides brasiliensis cell wall fraction. Clin Immunol 2006 118 : 324 31.
142. Teixeira JE, Martinez R, Camara LM, Barbosa JE. Expression of complement receptor type 1 (CR1) on erythrocytes of paracoccidioidomycosis patients. Mycopathologia 2001 152 : 125 33.
143. Chequer-Bou-Habib D, Oliveira-Neto MP, Ferreira-da-Cruz MF, Galvao-Castro B. The possible role of circulating immune complexes in the deficiency of cell-mediated immunity in paracoccidioidomycosis. Braz J Med Biol Res 1989 22 : 205 12.
144. Cosio FG, Shen XP, Birmingham DJ, Van Aman M, Hebert LA. Evaluation of the mechanisms responsible for the reduction in erythrocyte complement receptors when immune complexes form in vivo in primates. J Immunol 1990 145 : 4198 206.
145. Nardin A, Lindorfer MA, Taylor RP. How are immune complexes bound to the primate erythrocyte complement receptor transferred to acceptor phagocytic cells? Mol Immunol 1999 36 : 827 35.
146. Mold C, Gurulé C, Otero D, Du Clos TW. Complement-dependent binding of C-reactive protein complexes to human erythrocyte CR1. Clin Immunol Immunopathol 1996 81 : 153 60.
147. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jirovecii) for Pneumocystis from humans. Emerg Infect Dis 2002 8 : 891 6.
148. Gigliotti F, Wright TW. Immunopathogenesis of Pneumocystis carinii pneumonia. Expert Rev Mol Med 2005 7 : 1 16.
149. Lasbury ME, Durant PJ, Tschang D et al. Expression and activation of complement protein and alveolar damage during Pneumocystis pneumonia. J Eukaryot Microbiol 2006 53 (Suppl. 1 S136 7.
150. Wells J, Haidaris CG, Wright TW, Gigliotti F. Complement and Fc function are required for optimal antibody prophylaxis against Pneumocystis carinii pneumonia. Infect Immun 2006 74 : 390 3.
151. Laursen AL, Obel NS, Holmskov U, Jensenius JC, Aliouat elM, Andersen PL. Activation of the respiratory burst by Pneumocystis carinii. Efficiency of different antibody isotypes, complement, lung surfactant protein D, and mannan-binding lectin. APMIS 2003 111 : 405 15.
152. Lund FE, Schuer K, Hollifield M, Randall TD, Garvy BA. Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P. carinii-specific antibody. J Immunol 2003 171 : 1423 30.
153. Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev 2007 20 : 115 32.
154. Bullock WE, Wright SD. Role of the adherence-promoting receptors, CR3, LFA-1, and p150,95, in binding of Histoplasma capsulatum by human macrophages. J Exp Med 1987 165 : 195 210.
155. Ignatov A, Keath EJ. Molecular cell biology and molecular genetics of Histoplasma capsulatum. Int J Med Microbiol 2002 292 : 349 61.
156. Long KH, Gomez FJ, Morris RE, Newman SL. Identification of heat shock protein 60 as the ligand on Histoplasma capsulatum that mediates binding to CD18 receptors on human macrophages. J Immunol 2003 170 : 487 94.
157. Marth T, Kelsall BL. Regulation of interleukin-12 by complement receptor 3 signaling. J Exp Med 1997 185 : 1987 95.
158. Bradsher RW, Chapman SW, Pappas PG. Blastomycosis. Infect Dis Clin North Am 2003 17 : 21 40.
159. Zhang MX, Klein B. Activation, binding and processing of complement component 3 (C3) by Blastomyces dermatitidis. Infect Immun 1997 65 : 1849 55.
160. Zhang MX, Brandhorst TT, Kozel TR, Klein BS. Role of glucan and surface protein BAD1 in complement activation by Blastomyces dermatitidis yeast. Infect Immun 2001 69 : 7559 64.
161. Newman SL, Chaturvedi S, Klein BS. The WI-1 antigen of Blastomyces dermatitidis yeasts mediates binding to human macrophage CD11b/CD18 (CR3) and CD14. J Immunol 1995 154 : 753 61.
162. Brandhorst TT, Wüthrich M, Finkel-Jimenez B, Warner T, Klein BS. Exploiting type 3 complement receptor for TNF-alpha suppression, immune evasion, and progressive pulmonary fungal infection. J Immunol 2004 173 : 7444 53.
163. Speth C, Rambach G, Lass-Flörl C, Dierich MP, Würzner R. The role of complement in invasive fungal infections. Mycoses 2004 47 : 93 103.